Public advocacy record
Advocacy Timeline
A cautious chronology of public-facing advocacy connected to Trevor Millar and ibogaine in Canada: what can be placed in the record, what remains an announcement, and where regulatory context matters.
Reading the record
Chronology is not endorsement.
This page distinguishes reported appearances, public statements, organizational activity, media coverage, and regulatory context from demonstrated outcomes. The scope is Trevor Millar and ibogaine advocacy in Canada, not a claim that ibogaine is authorized, effective, or appropriate for anyone.
For a broader orientation to the subject covered across this site, the main Trevor Millar and ibogaine overview provides the surrounding context. Readers looking for the principles behind this independent resource can also consult the approach to independence, clarity, and accuracy.
Ibogaine is a psychoactive alkaloid associated with plants in the Tabernanthe iboga tradition; background descriptions should not be mistaken for a regulatory determination. The general ibogaine reference entry is useful for basic terminology, while legal and medical questions require primary Canadian sources.
Public-facing milestones
What the available public record can support
-
Personal accounts enter a wider advocacy conversation
Trevor Millar has appeared publicly in discussions concerning ibogaine and recovery-oriented advocacy. Personal narrative, interviews, and advocacy language are part of the public record, but they are not substitutes for clinical evidence, regulatory authorization, or individualized medical advice.
-
Ambio Life Sciences is associated with the advocacy narrative
Public references connect Millar with Ambio Life Sciences and with efforts to make ibogaine more visible in policy and public discussion. Accounts of organizational founding or operations should be checked against dated corporate records, official statements, and contemporaneous reporting before being treated as settled chronology.
-
Visibility expands beyond private testimony
Public interviews and media coverage can show what was said, when it was said, and how advocacy was framed. They cannot independently establish the safety, efficacy, legality, or status of any program. This distinction is central when evaluating claims connected to Canadian access or future initiatives.
-
Meetings and advocacy are not regulatory decisions
Policy meetings, correspondence, and public appeals may be relevant to a timeline when documented. They should be read alongside the federal framework: Health Canada explains that controlled substances are governed through the controlled substances and precursor chemicals program, rather than through advocacy statements alone.
-
Announced research or treatment programs require independent confirmation
Any announced research, access pathway, or treatment program should be treated as preliminary unless a primary record confirms its status. The documentation to look for includes an authorized study listing, a regulator’s decision, a dated institutional release, or peer-reviewed publication—not merely a promotional or secondary account.
Verification lens
Separate advocacy from authorization.
Canada’s overdose response provides important context for why new approaches are discussed publicly. The federal substance-related harms data documents the wider public-health emergency driving those conversations, but it does not validate a particular drug, provider, or advocacy proposal.
For claims about a Canadian clinical trial, the most useful next step is to check a recognized study registry, the applicable regulator, and the study’s own status information. For claims about legal availability, readers should distinguish a request, a meeting, or a public campaign from a formal authorization or exemption.
Canadian context
Why the policy backdrop belongs in the timeline
Advocacy around ibogaine has unfolded alongside public concern about drug toxicity, access to care, and responses to overdose. That context can explain the urgency of certain public messages without converting those messages into evidence of benefit or safety.
Health Canada’s substance-use resources describe a policy environment shaped by prevention, treatment, harm reduction, enforcement, and the toxic illegal drug supply. Within that environment, any proposed research or access program remains subject to the applicable legal and regulatory process.
Public attention is evidence of a conversation—not proof of a regulatory or clinical conclusion.
Questions readers ask
Does this timeline establish that ibogaine is approved in Canada?
No. It records public advocacy and surrounding policy context. It does not establish regulatory approval, clinical efficacy, or suitability for any person. For a focused discussion of uncertainty and safety considerations, see the evidence and risks material.
How should public claims and announcements be read?
Separate what a speaker or organization says from what a regulator, court record, registry, or peer-reviewed source confirms. Announced future programs and undated claims deserve particular caution until independently verifiable documentation is available.
Where does concussion-related advocacy fit?
Concussion-related discussion is a distinct topic and should not be folded into broad conclusions about ibogaine. The public-facing ibogaine and concussion resource can be read alongside the separate questions of Canadian regulation, evidence, and ethical framing.
Keep the evidence trail visible.
This chronology is designed for readers who want to distinguish advocacy, public discussion, regulatory process, and verifiable documentation in Canada.